ctDNA monitoring using tumor-informed copy number analysis
Open Access
- 19 March 2026
- journal article
- method
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1429-1455
Abstract
Methods to detect circulating tumor DNA (ctDNA) enable minimally invasive responsive monitoring of cancer dynamics. However, sensitive and cost-effective methods are still lacking. Current methods for detecting cancer signals in shallow whole-genome sequencing (sWGS) data from cell-free DNA (cfDNA) via copy number aberration (CNA) analysis typically have a limit of detection of approximately 3% tumor fraction (TF). We developed informCNA, a bioinformatics method that leverages CNA information from sWGS of tumor or pre-treatment plasma samples with high TF as references, enabling ctDNA detection down to 0.2% TF across multiple cancer types. In 177 serial plasma samples from 18 patients with ovarian cancer, informCNA showed high concordance with the standard serum protein marker CA-125 and identified recurrence a median of 3.7 months earlier than CA-125 test. These results demonstrate the potential of personalized CNA analysis through sWGS for estimating ctDNA burden, enabling precise and cost-effective disease monitoring and early detection of relapse.Keywords
Funding Information
- Cancer Research UK (C507/A27657,C9545/A29580,SEBINT-2024/100003,C1287/A26886,EDDRPG-May24/100002 & C36857/A27548)
- NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
- NIHR Cambridge Biomedical Research Centre (NIHR203312)
- Mark Foundation For Cancer Research (RG95043)
- Cancer Research UK Cambridge Institute, University of Cambridge (C9685/A25177)
- Cancer Research UK Cambridge Institute, University of Cambridge (CTRQQR- 2021\100012)
- Addenbrooke's Charitable Trust, Cambridge University Hospitals (ACT 9800)
- CRUK City of London Major Centre Awards (C7893/A26233 and CTRQQR-2021\100004)
- CRUK-Royal College of Surgeons of England Clinician Scientist Fellowship (C64667/A27958)
- Breast Cancer Now Toby Robins Research Centre (CTR-Q5-Y3)
This publication has 41 references indexed in Scilit:
- Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk predictionCell, 2025
- The roles, challenges, and merits of the p valuePatterns, 2023
- Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stageEuropean Journal of Surgical Oncology, 2022
- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancerAnnals of Oncology, 2022
- Selective review of offline change point detection methodsSignal Processing, 2020
- Genomic and Functional Approaches to Understanding Cancer AneuploidyCancer Cell, 2018
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumorsNature Communications, 2017
- Integrated digital error suppression for improved detection of circulating tumor DNANature Biotechnology, 2016
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNature Medicine, 2014
- The landscape of somatic copy-number alteration across human cancersNature, 2010